Profile data is unavailable for this security.
About the company
Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.
- Revenue in PLN (TTM)46.86m
- Net income in PLN-92.11m
- Incorporated2010
- Employees230.00
- LocationRyvu Therapeutics SALeona Henryka Sternbacha 2KRAKOW 30-394PolandPOL
- Phone+48 123140200
- Fax+48 122974701
- Websitehttps://ryvu.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Poltreg SA | 1.40m | -13.55m | 234.11m | 23.00 | -- | 2.67 | -- | 167.34 | -2.91 | -2.91 | 0.300 | 18.77 | 0.0112 | 51.22 | 27.43 | 61,494.50 | -10.82 | -6.51 | -12.42 | -7.35 | -811.65 | -391.38 | -968.62 | -449.24 | 3.87 | -- | 0.0856 | -- | 40.04 | -- | -588.92 | -- | 214.26 | -- |
| Molecure SA | 1.31m | -18.31m | 244.46m | 111.00 | -- | 1.55 | -- | 186.81 | -1.17 | -1.17 | 0.0847 | 9.34 | 0.0085 | -- | 0.2818 | 11,788.92 | -11.94 | 2.52 | -12.47 | 2.64 | -25.76 | 97.54 | -1,398.86 | 12.84 | -- | -- | 0.0434 | -- | -18.85 | 237.24 | -19.67 | -- | -24.82 | -- |
| Mabion SA | 151.68m | 41.27m | 267.00m | 226.00 | 6.47 | 2.27 | 5.51 | 1.76 | 2.55 | 2.55 | 9.38 | 7.29 | 0.7691 | 4.84 | 9.12 | 671,146.00 | 20.93 | -7.19 | 31.17 | -16.79 | 75.54 | 58.10 | 27.21 | -14.27 | 1.51 | 8.35 | 0.2331 | -- | -7.50 | -- | 77.94 | -- | 40.86 | -- |
| Bioceltix SA | 0.00 | -12.73m | 276.67m | -- | -- | 19.44 | -- | -- | -3.45 | -3.45 | 0.00 | 3.45 | 0.00 | 170.52 | -- | -- | -112.58 | -- | -140.07 | -- | -- | -- | -- | -- | 5.96 | -- | 0.0071 | -- | -- | -- | -102.87 | -- | -- | -- |
| BIOTON SA | 181.64m | 2.28m | 300.52m | 358.00 | 132.13 | 0.4956 | 8.07 | 1.65 | 0.0265 | 0.0265 | 2.12 | 7.06 | 0.2228 | 0.9493 | 18.41 | 507,363.10 | 0.279 | -1.99 | 0.3437 | -2.47 | 40.11 | 45.33 | 1.25 | -8.61 | 0.2933 | 1.90 | 0.1018 | -- | -22.10 | -5.51 | 60.10 | -38.69 | 0.3284 | -- |
| Synthaverse SA | 58.61m | 4.76m | 315.86m | 239.00 | 71.47 | 3.02 | 27.74 | 5.39 | 0.0677 | 0.0677 | 0.8341 | 1.60 | 0.2732 | 1.66 | 2.76 | 245,217.60 | 2.22 | 3.53 | 2.55 | 4.32 | 60.00 | 55.62 | 8.12 | 9.59 | 0.9705 | 4.47 | 0.3834 | -- | 16.32 | 12.66 | -21.76 | -- | 111.77 | -- |
| Captor Therapeutics SA | 13.20m | -70.58m | 350.30m | 104.00 | -- | 5.57 | -- | 26.54 | -16.42 | -16.42 | 3.04 | 14.90 | 0.1256 | -- | 3.59 | 126,932.70 | -67.13 | -- | -82.96 | -- | 52.28 | -- | -534.69 | -- | -- | -- | 0.0518 | -- | 44.15 | -- | -96.65 | -- | -- | -- |
| Scope Fluidics SA | 516.00k | -18.79m | 442.69m | 40.00 | -- | 5.47 | -- | 857.93 | -6.89 | -6.89 | 0.1893 | 29.69 | 0.0023 | 2.73 | 0.1827 | 12,900.00 | -8.39 | 52.74 | -8.61 | 57.32 | -265.89 | -420.87 | -3,640.50 | 30,134.78 | 14.60 | -- | 0.0289 | -- | 27.72 | -- | -105.76 | -- | 89.99 | -- |
| Celon Pharma SA | 216.57m | -28.12m | 792.40m | 513.00 | -- | 1.78 | 28.29 | 3.66 | -0.5508 | -0.5508 | 4.24 | 8.73 | 0.3574 | 2.08 | 7.23 | -- | -4.64 | -2.24 | -5.57 | -2.57 | 68.92 | 70.71 | -12.99 | -7.79 | 1.89 | -- | 0.0543 | -- | 11.29 | 11.57 | 28.40 | -- | -13.42 | -- |
| Ryvu Therapeutics SA | 46.86m | -92.11m | 1.12bn | 230.00 | -- | 4.33 | -- | 23.98 | -4.05 | -4.05 | 2.06 | 11.23 | 0.1067 | 13.34 | 9.16 | 203,739.10 | -20.98 | -21.88 | -24.12 | -25.20 | 44.80 | -6.28 | -196.57 | -284.20 | 3.96 | -- | 0.0362 | -- | 20.32 | -9.50 | -9.94 | -- | 53.71 | -- |
| Selvita SA | 351.85m | 70.03m | 1.30bn | 847.00 | 18.51 | 3.96 | 11.22 | 3.68 | 3.81 | 3.81 | 19.17 | 17.82 | 0.5763 | 9.92 | 4.59 | 415,410.90 | 11.47 | -- | 14.09 | -- | 79.78 | -- | 19.90 | -- | 1.54 | 17.11 | 0.4073 | -- | -3.48 | -- | 130.55 | -- | -- | -- |
Data as of May 06 2024. Currency figures normalised to Ryvu Therapeutics SA's reporting currency: Polish New Zloty PLN
31.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Allianz Polska TFI SAas of 12 May 2023 | 2.13m | 9.22% |
| Aviva Investors Poland Towarzystwo Funduszy Inwestycyjnych SAas of 31 Dec 2022 | 1.53m | 6.63% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.14m | 4.91% |
| FORUM TFI SAas of 31 Dec 2022 | 1.13m | 4.90% |
| Vienna PTE SA Vienna Insurance Groupas of 31 Dec 2021 | 370.71k | 1.60% |
| Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SAas of 30 Jun 2023 | 359.97k | 1.56% |
| Generali PTE SAas of 29 Dec 2023 | 340.28k | 1.47% |
| Pekao TFI SAas of 30 Jun 2023 | 124.48k | 0.54% |
| Rockbridge TFIas of 30 Jun 2023 | 70.84k | 0.31% |
| TFI PZU SAas of 30 Jun 2023 | 55.52k | 0.24% |
More ▼
Data from 31 Dec 2021 - 31 Dec 2023Source: FactSet Research Systems Inc.
